119 related articles for article (PubMed ID: 22830523)
1. Retinal angiomatous proliferation responds safely to a double dose (1.0 mg) of ranibizumab.
Hsu TK; Liu JH; Lei J; Chao HM
Clin Exp Optom; 2013 Jan; 96(1):112-6. PubMed ID: 22830523
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.
Gharbiya M; Allievi F; Recupero V; Martini D; Mazzeo L; Gabrieli CB
Retina; 2009 Jun; 29(6):740-9. PubMed ID: 19516116
[TBL] [Abstract][Full Text] [Related]
3. Macular hole after intravitreal ranibizumab injection for polypoidal choroidal vasculopathy.
Cho JH; Park SE; Han JR; Kim HK; Nam WH
Clin Exp Optom; 2011 Nov; 94(6):586-8. PubMed ID: 21517972
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of retinal angiomatous proliferation by photodynamic therapy.
Gómez-Ulla F; Abraldes MJ; Fernández M; Olmedo M
Optom Vis Sci; 2006 Aug; 83(8):546-9. PubMed ID: 16909080
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Br J Ophthalmol; 2014 Jul; 98(7):956-60. PubMed ID: 24599418
[TBL] [Abstract][Full Text] [Related]
6. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
Engelbert M; Zweifel SA; Freund KB
Retina; 2009; 29(10):1424-31. PubMed ID: 19898180
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy, and intravitreal triamcinolone with photodynamic therapy for the treatment of retinal angiomatous proliferation.
Rouvas AA; Chatziralli IP; Theodossiadis PG; Moschos MM; Kotsolis AI; Ladas ID
Retina; 2012 Jun; 32(6):1181-9. PubMed ID: 22466469
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation.
Cho HJ; Yoo SG; Kim HS; Kim JH; Kim CG; Lee TG; Kim JW
Am J Ophthalmol; 2015 Feb; 159(2):285-92.e1. PubMed ID: 25447115
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation.
Saito M; Shiragami C; Shiraga F; Kano M; Iida T
Am J Ophthalmol; 2010 Mar; 149(3):472-81.e1. PubMed ID: 20053392
[TBL] [Abstract][Full Text] [Related]
10. Treatment Effects in Retinal Angiomatous Proliferation Imaged with OCT Angiography.
de Jong JH; Braaf B; Amarakoon S; Gräfe M; Yzer S; Vermeer KA; Missotten T; de Boer JF; van Velthoven MEJ
Ophthalmologica; 2019; 241(3):143-153. PubMed ID: 30227415
[TBL] [Abstract][Full Text] [Related]
11. [Photodynamic therapy in retinal angiomatous proliferations].
Kürzinger GR; Lang GK; Lang GE
Klin Monbl Augenheilkd; 2008 Feb; 225(2):159-64. PubMed ID: 18293269
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.
Parodi MB; Iacono P; Menchini F; Sheth S; Polini G; Pittino R; Bandello F
Acta Ophthalmol; 2013 May; 91(3):267-73. PubMed ID: 21951313
[TBL] [Abstract][Full Text] [Related]
13. Phase-Resolved Doppler Optical Coherence Tomographic Features in Retinal Angiomatous Proliferation.
Amarakoon S; de Jong JH; Braaf B; Yzer S; Missotten T; van Velthoven ME; de Boer JF
Am J Ophthalmol; 2015 Nov; 160(5):1044-1054.e1. PubMed ID: 26210860
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
15. [Intravitreal injection of bevacizumab (Avastin) for retinal angiomatous proliferation].
Amselem L; Díaz-Llopis M; Cervera E; García-Delpech S; Moratal-Peiro B; Palomares P
Arch Soc Esp Oftalmol; 2008 Jan; 83(1):53-6. PubMed ID: 18188796
[TBL] [Abstract][Full Text] [Related]
16. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation.
Freund KB; Ho IV; Barbazetto IA; Koizumi H; Laud K; Ferrara D; Matsumoto Y; Sorenson JA; Yannuzzi L
Retina; 2008 Feb; 28(2):201-11. PubMed ID: 18301024
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation.
Costagliola C; Romano MR; dell'Omo R; Cipollone U; Polisena P
Am J Ophthalmol; 2007 Sep; 144(3):449-51. PubMed ID: 17765426
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
19. A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD.
Roberts P; Mittermueller TJ; Montuoro A; Sulzbacher F; Munk M; Sacu S; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2014 Sep; 55(10):6623-30. PubMed ID: 25190663
[TBL] [Abstract][Full Text] [Related]
20. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.
Parravano M; Oddone F; Tedeschi M; Schiano Lomoriello D; Chiaravalloti A; Ripandelli G; Varano M
Retina; 2009 Mar; 29(3):329-34. PubMed ID: 19092732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
